Biotech Stock News: NervGen Pharma (TSXV: NGEN) Receives Approval to Proceed to the Final Dose Cohort in Phase 1 Clinical Trial of NVG-291 and Reports Q1 2022 Results


Vancouver, British Columbia – May 12, 2022 (Newsfile Corp.) ( Newswire) NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF), a clinical stage biotech company dedicated to developing a first-in-class neuroreparative drug to treat nervous system damage, today announced it has received approval from the Safety Review Committee to advance to the third and highest dose cohort in the multiple ascending dose portion of its Phase 1 clinical trial of the Company’s proprietary lead compound, NVG-291.

: Twitter stock falls after Elon Musk puts buyout deal ‘temporarily on hold’

Previous article

Brett Arends’s ROI: This idiot-proof portfolio has beaten traditional stocks and bonds over 50 years

Next article

You may also like


Leave a reply

Your email address will not be published. Required fields are marked *

More in News